Esperion Therapeutics

Rising Digital Adoption And Global Partnerships Will Shape Future Markets

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

04 May 25

Updated

09 Dec 25

Views

283

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

53.7%

7D

-0.3%

Loading

1Y

53.7%

7D

-0.3%

You can edit this narrative until Dec 10 2:10 AM. Then, changes will post as Updates.

Author's Valuation

US$6.541.9% undervalued

AnalystConsensusTarget Fair Value

Shared on 09 Dec 25

Fair value Increased 5.81%

ESPR: Rising Overweight Ratings Will Support Bullish Sentiment Toward Shares

Analysts have nudged their price target for Esperion Therapeutics higher to approximately $6.50 per share from about $6.15, citing supportive Street research, including recent Overweight initiations and target increases. These changes reflect confidence in the company’s longer term earnings multiple despite slightly tempered growth and margin assumptions.

Shared on 25 Nov 25

Fair value Increased 0.70%

ESPR: Overweight Ratings And Positive Developments Will Strengthen Bullish Outlook For Shares

Analysts have raised their price target for Esperion Therapeutics from $7 to $9 per share. This reflects improved expectations for the company's revenue growth and fair value based on recent positive coverage and outlook updates.

Shared on 09 Nov 25

Fair value Increased 5.22%

ESPR: Price Target Increase Will Drive Renewed Confidence In Future Performance

Analysts have raised their price target for Esperion Therapeutics from $7 to $9, citing improved growth and profitability expectations. Analyst Commentary Bullish Takeaways Bullish analysts have increased their price targets, reflecting growing confidence in the company's outlook and execution capabilities.

Shared on 06 Aug 25

Fair value Increased 0.25%

Esperion Therapeutics' consensus price target has increased as analysts now assign a higher future P/E despite a decline in net profit margin, resulting in the APT rising from $5.79 to $6.50. What's in the News Esperion Therapeutics was dropped from the S&P Pharmaceuticals Select Industry Index.

AnalystConsensusTarget Fair Value

US$6.5

41.9% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

18.38%

Pharma revenue growth rate

0.63%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.96%

Calculation

US$198.99m

Earnings '28

x

16.31x

PE Ratio '28

=

US$3.24b

Market Cap '28

US$3.24b

Market Cap '28

/

407.85m

No. shares '28

=

US$7.96

Share Price '28

US$7.96 Share Price '28

Discounted to 2025 @ 6.96% p.a.

=

US$6.50

Fair Value '25